申请人:Medizinische Universität Wien
公开号:EP2177218A1
公开(公告)日:2010-04-21
The present invention relates to the use of an agent capable of enhancing the PKA-p38-CREB pathway, suppressing the Fyn-RhoA-Rock and/or PKC-alpha-MARCKS pathways or Ephrin-B3 for the manufacture of a pharmaceutical composition for the treatment of damaged myelin sheaths, characterized in that, the agent neutralizes the effect of inhibitors of the regeneration of damaged myelin sheaths by oligodendrocytes, and wherein the inhibitors are selected from myelin associated inhibitors, in particular Ephrin-B3, and inhibitors of the glial scar, in particular Sema3A, and kits suitable for the treatment of damaged myelin sheaths.
本发明涉及一种能够增强PKA-p38-CREB通路、抑制Fyn-RhoA-Rock和/或PKC-α-MARCKS通路或Ephrin-B3的制剂在制造治疗受损髓鞘的药物组合物中的用途,其特征在于:该制剂能中和抑制少突胶质细胞再生受损髓鞘的抑制剂的作用,其中抑制剂选自髓鞘相关抑制剂,特别是 Ephrin-B3,以及胶质瘢痕抑制剂,特别是 Sema3A,以及适用于治疗受损髓鞘的试剂盒。